HomeProductsBioactive CompoundsTGF-beta/Smad PathwayBcr-AblAsciminib
Chemical structure of CAS 1492952-76-7

Asciminib

CAS No.1492952-76-7
MDL No.N/A
MFC20H18ClF2N5O3
MW449.80
InChI KeyVOVZXURTCKPRDQ-CQSZACIVSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1492952-76-7
Product NameAsciminib

Biological Targets

ABL1·BCR

Associated Conditions

chronic myelogenous leukemia·Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive·kidney disease·neoplasm·biliary tract cancer·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing -compound mutations.

American journal of cancer research • Vol. 11, Issue 9 • 2021
PMID: 34659899PMC: PMC8493398

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.

Blood • Vol. 138, Issue 21 • 2021
PMID: 34407542PMC: PMC9728405DOI: 10.1182/blood.2020009984

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.

Leukemia research • Vol. 98 • 2020
PMID: 33096322DOI: 10.1016/j.leukres.2020.106458

Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.

Journal of medicinal chemistry • Vol. 63, Issue 15 • 2020
PMID: 32657579DOI: 10.1021/acs.jmedchem.0c00967

Documentation

Similar Products